40
Views
8
CrossRef citations to date
0
Altmetric
Original Article

A double-blind, placebo-controlled study of the clinical efficacy of ciclopirox olamine (1.5%) shampoo for the control of scalp psoriasis

, , &
Pages 163-167 | Received 29 Oct 1997, Accepted 21 Apr 1998, Published online: 12 Jul 2009
 

Abstract

The efficacy of ciclopirox olamine (1.5%) shampoo was evaluated in patients with scalp psoriasis using a placebo-controlled ‘whole-head’ clinical trial design. Unmedicated shampoo was used during a 2-week run-in period followed by a 4-week double-blind, randomized treatment period with trial shampoos used thrice weekly. During treatment, clinical assessments of overall scalp psoriasis and change from baseline as well as plaque size and the degree of scaling were performed by trained technicians while patients self-assessed overall scalp psoriasis and scalp itching, gave an overall opinion of treatment and assessed the dryness/greasiness of their hair. For ciclopirox olamine only, there was significant (P < 0.05) improvement over baseline for clinical assessment of overall scalp psoriasis (day 29) and degree of scaling (days 8, 15 and 29) and for patients’ self-assessments of overall scalp psoriasis (days 15 and 29) and scalp itching (day 15), but differences from placebo were not significant. Ciclopirox olamine tolerability and acceptability were good.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.